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Introduction: Although genetic information is essential for molecu-
lar targeted therapy for personalized medicine, tissue sampling for 
genetic analysis remains challenging. We investigated the utility of 
bronchoscopic sampling in non–small-cell lung cancer (NSCLC) 
patients compared with conventional histological materials for mul-
tiple genetic analyses.
Methods: Patients with NSCLC proven by onsite cytological evalu-
ation during bronchoscopic survey were eligible for this study. After 
conventional needle aspiration biopsy by flexible bronchofiberscopy 
of primary lesions or convex-probe endobronchial ultrasound of 
lymph nodes, the used needle was rinsed with saline, and the ultra-
microsample (uMS) was used for cytological diagnosis and genetic 
analysis. Gene mutations and fusion genes were examined by high-
resolution melting analysis and direct sequencing. The results from 
the uMS and those from conventional histological samples were 
compared.
Results: A total of 134 lesions (48 primary and 86 metastatic) 
were analyzed. Adenocarcinoma (n = 80), squamous-cell carci-
noma (n = 43), and NSCLC (n = 11) samples were pathologi-
cally confirmed in histological cores; however, malignancies 
were detected in only 45 (34%) of the corresponding uMS. In 
62 samples, genetic disorders, including epidermal growth 
factor receptor (n = 21), K-ras (n = 11), and BRAF mutations 
(n = 1); anaplastic lymphoma kinase (n = 5), receptor tyrosine 
kinase (n = 1), and RET fusion genes (n = 1); and silent mutations 
(n = 22), were identified. In total, 1474 molecular tests were per-
formed, and 1464 tests (99.3%) were identical for both histologi-
cal samples and uMS.
Conclusion: Bronchoscopic uMS (biopsy needle rinsed fluids) are 
useful for multiple genetic examinations in NSCLC.
Key Words: Bronchoscopic ultrasound, Bronchoscope, Biomarker, 
Microsampling.
(J Thorac Oncol. 2014;9: 26–32)
The rise of molecular targeted chemotherapy has changed the fundamental concept of treatment in non–small-cell lung 
cancer (NSCLC). A relationship between epidermal growth 
factor receptor (EGFR) and EGFR–tyrosine kinase inhibitors 
was verified by large-scale clinical trials.1,2 Additional rela-
tionships between companion diagnoses are under investiga-
tion, and treatment with new agents are under development, 
including crizotinib for anaplastic lymphoma kinase (ALK), 
c-ros oncogene 1, or receptor tyrosine kinase (ROS1) fusion 
gene–positive lung cancer3,4; sunitinib for ret proto-oncogene 
(RET) fusion gene–positive lung cancer5,6; and vemurafenib 
for BRAF mutation (V600E)–positive lung cancer.7
Therefore, the existence of gene mutations or fusion 
genes becomes a key factor for treatment decisions in NSCLC. 
However, the methodology used to detect such gene mutations 
is still under development. Although operational specimens 
are suitable for genetic analysis with respect to sample assur-
ance and containing massive tumor cells, genetic analysis 
before the operation is preferable for acquisition of genetic 
information for initial treatment planning, an issue in the 
application of companion biomarkers. Bronchoscopic sam-
ples are general samples that may provide definitive diagnoses 
and that can be obtained during preoperative stages of clini-
cal evaluation. To overcome this issue, molecular analyses of 
microhistological samples (e.g., bronchoscopic histological 
samples) have been established, and we have reported the util-
ity of endobronchial ultrasound-guided transbronchial needle 
aspiration (EBUS-TBNA) sampling, which can be challeng-
ing, for molecular analysis.8,9 Thus, establishing a method-
ology for the molecular analysis of cytological specimens is 
the next step to developing personalized medicine by using 
genetic information and molecular targeted therapy.10
The aim of this study was to determine the utility of 
bronchoscopic ultra-microsamples (uMSs), which were 
obtained from rinsed fluid of the used needle as well as endo-
scopic histological samples (histological cores) for multiple 
molecular profiling analyses in NSCLC.
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PATIENTS AND METHODS
Patients
The patient eligibility criteria were as follows: (1) 
patients who had undergone conventional bronchoscopy for 
the diagnosis of primary lesions or EBUS-TBNA for the diag-
nosis of metastatic lymph nodes; (2) patients from whom both 
histological and cytological specimens could be obtained; (3) 
patients with malignant cells proven by rapid onsite cytol-
ogy in both cytological and histological specimens; and (4) 
patients providing informed consent for the study. A well-
trained operator carried out all sampling procedures under 
local anesthesia and conscious sedation, without intubation. 
In general, all procedures were performed in the outpatient 
clinics of our hospitals.
Bronchoscopic Sampling from 
the Primary Tumor
For the diagnosis of primary lung lesions, including 
both peripheral and central lesions, transbronchial forceps 
biopsy (TBFB) was performed with a flexible bronchoscope 
(BFS-type260; Olympus, Tokyo, Japan). to obtain histological 
specimens after TBNA to obtain cytological specimens, and 
these procedure were repeated until malignant cells were con-
firmed by rapid onsite cytology with a touch smear (for TBFB) 
or smear (for TBNA) slide stained with Diff-Quik (Sysmex 
Corporation, Kobe, Japan). In eligible cases, a portion of the 
TBFB sample was preserved on ice immediately and stored 
at −80°C with 1 ml lysis buffer (MagNA Pure Compact RNA 
Isolation Kit; Roche Diagnostics, Mannheim, Germany); this 
sample was the control sample for molecular analysis (endo-
scopic histological core; core), whereas the remaining por-
tion of the TBFB sample was used for pathological diagnosis. 
Used TBNA needles were rinsed in a 20-ml saline bottle and 
washed after every TBNA procedure. The remnant cells in 
the bottle were referred as considered the uMS in this study; 
these cells were well mixed and divided into three bottles: 
5 ml for bacterial culture, 5 ml for the diagnosis, and 10 ml 
for molecular analysis. The uMS for molecular analysis was 
equally divided and immediately centrifuged for 2 minutes at 
2000 rpm. The obtained cell pellet was stored at −80°C. This 
uMS preparation procedure was performed within 20 minutes 
of sample collection. Pathologists confirmed the final cytologi-
cal diagnosis of the uMS, and the results, including those from 
molecular profiling, were compared with those of histological 
core samples as a control. Malignant diagnosis in cytological 
specimen was defined by findings of strongly suggestive of 
malignancy (class IV) or conclusive for malignancy (class V) 
according to Papanicolaou’s classification. This sampling 
sequence is described in the left (TBNA) and center (TBFB) 
columns of Figure 1.
EBUS-TBNA from Metastatic Nodes
For the diagnosis of metastatic lymph nodes, includ-
ing both mediastinal and hilar nodes, a convex-probe EBUS 
(BF-UC260F-OL8, Olympus), dedicated ultrasound scanner 
(EU-C2000/EU-C60; Olympus), and dedicated 22-gauge 
needle equipped with an internal stylet (NA-201SX-4022; 
Olympus) were used to obtain histological and cytological 
specimens. Malignant cells in TBNA droplets from every 
puncture were confirmed by stained smears in onsite screen-
ing. Histological cores were preserved on ice immediately and 
stored at −80°C; these cores were used for control samples 
in molecular analyses. Used needles were rinsed in a 20-ml 
saline bottle for every puncture, and the uMSs were obtained 
and divided into three bottles for analysis using the same 
methods as those used for bronchoscopic samples. This sam-
pling sequence is described in the right column of Figure 1.
DNA and RNA Extraction
The uMS pellet and tissue from the core were used to 
obtain DNA or RNA. These samples were homogenized with 
FIGURE 1.  Sampling sequence for primary lesions 
and metastatic nodes. For primary lesions, TBNA 
with needle and TBFB was performed by using con-
ventional bronchofiberscopy. For metastatic nodes, 
EBUS-TBNA was performed. Used needles were 
washed in saline and divided into three bottles, and 
these uMSs were used for bacterial culture, cyto-
logical analysis, and molecular analysis. All samples 
in this study were confirmed as malignant cells in 
each modality by rapid onsite cytological evalua-
tion. TBNA, transbronchial needle aspiration; TBFB, 
transbronchial forceps biopsy; EBUS, endobronchial 
ultrasound-guided; uMS, ultra-microsamples.
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a MagNA Lyser for 60 seconds at 6500 rpm and placed on a 
cooling block for 1 minute. Supernatants (100 μl) were used 
for DNA extraction with a MagNA Pure Compact Nucleic 
Acid Isolation Kit. Supernatants (350 μl) from homogenates 
were centrifuged and RNA was extracted using a MagNA Pure 
Compact RNA Isolation Kit. cDNA cloning was performed 
with a First Strand cDNA Synthesis Kit (Roche). Extracted 
DNA and cDNA were stored at 4°C.
Detection and Sequencing of Mutations
For the screening of mutations or fusion genes, we 
applied high-resolution melting (HRM) analysis11 for both 
DNA and RNA analysis. We used a protocol and primer 
sequences that have been described previously to detect EGFR 
(4 primer sets),12 KRAS (2 primer sets),11,12 and BRAF (2 primer 
sets)13 mutations in DNA extracts in one run. For reverse-
transcriptase polymerase chain reaction (RT-PCR) analysis, 
optimized primer sets based on previously reported primer 
sets were used in two runs (ALK and ROS1, RET). For detec-
tion of the ALK fusion gene, a new forward primer (EML4-
ALK v3b1; 5′-CAAGCATAAAGATGTCATCATCAAC-3′) 
was added to the eight previously reported primers,14 
and multiplex RT-PCR was performed with these nine 
primer sets in one test. For ROS1 fusion gene detec-
tion, two optimized forward primers (TPM3-ROS1, 
5′-GCTGAGTTTGCTGAGAGATCGGTAG-3′ and LRIG3-
ROS1, 5′-CCAACACAGATGAGACCAACTTGC-3′) and 
four reported primers (SDC4-ROS1, SLC34A2-ROS1, CD74-
ROS1, and EZR-ROS1)15 with an optimized reverse primer 
(5′-CGCAGCTCAGCCAACTCTTTGTC-3′) to avoid the 
amplification of nonspecific products. These six primer sets 
were used in multiplex RT-PCR in one test. The RET fusion 
gene was tested by multiplex RT-PCR with three reported 
primer sets in one test.15 After PCR amplification, purified 
products were then sequenced with a capillary sequencer 
(3130 Genetic Analyzer; Life Technologies, Carlsbad, CA), 
and the actual mutation sequence or fusion locus was defined. 
All mutation/fusion gene detections were repeated thrice to 
validate the results. In total, three runs, including 11 molecu-
lar tests, were needed for each sample.
Ethics Committee Approval
The bioethics committee of Chiba University Graduate 
School of Medicine approved this research (No. 275). Written 
consent was obtained from patients, and all samples were 
coded and managed independently.
RESULTS
Patients and Pathological Diagnosis
From November 2010 to October 2012, 146 patients 
(149 samples) were enrolled in this study; samples consisted 
of 52 primary tumors and 97 metastatic lymph nodes. By 
the revealed final pathological diagnosis, 15 samples were 
omitted and 134 samples were eligible for this study (107 
from men and 27 from women). The reasons for the omit-
ted cases included no malignant findings obtained in the 
histological core of the primary tumor (n = 4), metastasis 
of renal cell carcinoma (n = 1), gastric carcinoma (n = 1), 
small-cell lung cancer (n = 2), sarcoma (n = 1), malignant 
lymphoma (n = 1), and inflammation with severe atypia 
(n = 5). The latter 11 samples were diagnosed from core sam-
ples obtained by EBUS-TBNA. Final histological diagnoses 
in eligible samples of primary tumors and metastatic nodes 
consisted of adenocarcinomas in 30 and 50 (63% and 58%), 
squamous cell carcinoma in 16 and 27 (33% and 31%), and 
other cancers in 2 and 9 (4% and 10%) samples, respectively. 
Target lesion and size of primary tumor and metastatic node 
are listed in Supplementary Table 1 (Supplemental Digital 
Content 1, http://links.lww.com/JTO/A490). TBNA or 
EBUS-TBNA was attempted an average (±SD) of 2.37 ± 1.15 
or 6.45 ± 3.26 times, and malignant cells were confirmed 1.71 
times (81%) or 3.92 times (72%), respectively. No pathogens 
were cultured from uMSs in this study. Sample enrollment 
and pathological results are illustrated in Figure 2.
DNA and RNA Extraction
DNA was successfully extracted from both uMSs 
and histological cores for every sample. DNA was eluted in 
a final volume of 200 μl, and extracted DNA was obtained 
at concentrations of 9.3 ± 8.8 ng/μl from core samples and 
3.7 ± 3.4 ng/μl from uMSs in bronchoscopic samples of pri-
mary tumors. In EBUS-TBNA samples of metastatic nodes, 
the extracted DNA concentrations were 24.8 ± 27.3 ng/μl from 
cores and 5.2 ± 4.1 ng/μl from uMSs. RNA was also success-
fully extracted from both uMSs and histological cores for every 
sample. RNA was eluted in a final volume of 50 μl. Extracted 
RNA was obtained at concentrations of 64.0 ± 45.0 ng/μl 
from cores and 12.8 ± 9.9 ng/μl from uMSs by bronchos-
copy or 129.8 ± 140.3 ng/μl from cores and 18.1 ± 14.5 ng/μl 
from uMSs by EBUS-TBNA. These results are summarized 
in Supplementary Table 2 (Supplemental Digital Content 1, 
http://links.lww.com/JTO/A490).
Mutation/Fusion Gene Detection
We confirmed that our primer sets work properly by 
using following artificial sequences as the positive control; 
EGFR Exons 18–21 Genomic DNA Reference Standards, 
K-Ras Codons 12 & 13 Genomic DNA Reference Standards, 
B-Raf Codon 600 Genomic DNA Reference Standards 
(Horizon Diagnostics, Cambridge, United Kingdom), 
EML4-ALK (variant 1, 2, 3a), KIF5B-ALK, KIF5B-RET, 
CCDC6-RET, TPM3-ROS1, SDC4-ROS1, SLC34A2-
ROS1, CD74-ROS1, EZR-ROS1, LRIG3-ROS1 (GenScript, 
Piscataway, NJ). HRM curve of these control sequences are 
illustrated in Supplementary Figure 1 (Supplemental Digital 
Content 3, http://links.lww.com/JTO/A492). In total, 73 
genetic disorders were identified, including EGFR mutations 
(n = 21), KRAS mutations (n = 11), BRAF mutations (n = 1), 
ALK fusion genes (n = 5), ROS1 fusion genes (n = 1), RET 
fusion genes (n = 1), and silent mutations (n = 22). Double 
mutations (including silent mutation) were detected in 12 
samples (Table 1), and HRM-PCR curves (melting peaks) of 
each mutation and fusion, along with the identified sequences, 
are shown in Figure 3.
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Comparison of the Result from 
Histological Cores and uMSs
The results of comparisons between cores and uMSs are 
summarized in Table 2. Final cytological evaluations of uMSs 
revealed only 34% of malignant cells, despite that all eligible 
samples showed malignant findings in the final cytological 
and histological evaluation of cores. In uMSs from primary 
tumors, 25% (12 of 48) of malignant cells were confirmed, 
whereas 38% (33 of 86) of malignant cells were confirmed in 
uMSs from metastatic lymph nodes. In total, 1474 genetic tests 
were conducted, and complete concordance was confirmed in 
1464 tests (99.3%). Major discrepancies occurred in six tests 
(0.4%); mutations were detected only in the histological core 
in four tests or only in uMSs in two tests. All major discrep-
ancies occurred in samples from primary tumors. Minor dis-
crepancies occurred in four tests (0.3%), and although these 
mutations were identified by HRM-PCR, their sequences were 
not identified by direct sequencing. This discrepancy occurred 
in uMSs, and the sequences were successfully identified in 
histological cores.
DISCUSSION
Through this study, we showed the utility of uMSs 
and bronchoscopic histological cores with respect to mul-
tiple molecular profiling analyses in NSCLC. Our data sug-
gested that molecular analysis using uMSs provides accurate, 
easy-to-obtain data that can be used to replace conventional 
sampling methods in the development of molecular targeted 
therapies for patients with NSCLC.
The methodology was designed such that the uMS con-
tained malignant cells, both through the sampling procedure 
itself and through onsite cytological evaluation. Generally, the 
primary objective of rinsing the biopsy needle is to clean the 
needle for the next biopsy procedure; usually this rinse liquid is 
considered waste. Our method allowed us to conduct molecu-
lar analysis using this waste without any additional biopsies or 
without repeated biopsies using other modalities. A compari-
son of the final pathological diagnosis and rapid onsite cytolog-
ical evaluation revealed that only 34% (45 of 134) of samples 
were confirmed as malignant, an issue that has been previously 
reported;16 however, our study allowed us to perform molecu-
lar testing by a logically well-designed sampling procedure 
known as the “recycled method,” which enabled us to obtain 
malignant cells. uMS analysis may to increase the sensitivity to 
detect cancer through the molecular analysis in cases where we 
do not get enough tissue even for standard cytology.
In this study, 0.7% (10) of tests showed molecular pro-
file discrepancies between histological cores and uMSs. Three 
minor discrepancies were caused by problems with sensitiv-
ity, which will be discussed later. We also observed about 
six major discrepancies between samples, and all these dis-
crepancies occurred during sampling from primary lesions. 
For sampling from primary lesions, it consisted of two steps: 
TBFB and TBNA. In contrast, EBUS-TBNA was consisted 
of one step in which both histological and cytological speci-
mens were obtained and no major discrepancies occurred in 
uMSs versus EBUS-TBNA samples. Thus, we assumed that 
the separate biopsy procedure was one cause of the discrep-
ancies between bronchoscopic biopsy samples and uMSs. In 
addition, we retrospectively investigated the six major dis-
crepancy cases; TBNA was attempted an average of 2 ± 1.09 
times, and malignant cells were detected 1.33 times. These 
numbers are lower than those for EBUS-TBNA (6.45 ± 3.26 
and 3.92 times, respectively). Multiple appropriate punctures 
may increase the total cell amount in uMS collected, and the 
collection of more cells may prevent the occurrence of major 
discrepancies. Notably, four of the major discrepancies were 
mutations detectable only in uMSs. Clinically, biopsy cores 
contain some normal lung tissue, and the rate of tumor occur-
rence is variable. Even when touch smear cytology shows 
FIGURE 2.  Case enrollment. From 149 samples, 15 samples 
were omitted because of the pathological/cytological final 
evaluation. Only non–small-cell lung cancer samples were 
enrolled in this study. Ad, adenocarcinoma; Sq, squamous-
cell carcinoma; TBNA, transbronchial needle aspiration; TBFB, 
transbronchial forceps biopsy; EBUS-TBNA, endobronchial 
ultrasound-guided transbronchial needle aspiration; uMS, 
ultra-microsample.
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malignant cells, whole core samples sometimes contain very 
small amounts of tumor cells, and this may be one cause 
for the faults observed in molecular analysis. In this regard, 
EBUS-TBNA is a preferable sampling procedure, avoiding 
quality discrepancies between core samples and uMSs.
The relationship between molecular biomarkers and 
molecular targeting agents has been well recognized, and the 
importance of molecular testing has increased. Therefore, a 
universal and accessible method through which to analyze 
samples is needed. Because of this, molecular testing costs 
have become an issue. The goal of molecular testing is to 
accomplish individualization and optimization of treatment 
using molecular targeting agents, which can be expensive. 
Obviously, less-expensive testing is favorable; in the United 
States, EGFR mutation gene tests cost approximately $700. 
Our PCR-based gene profiling method used a universal DNA/
RNA extraction kit and conventional PCR methods and con-
sisted of automated DNA/RNA extraction and three runs (1 
for DNA and 2 for RNA) for all 11 molecular tests in each 
case. Thus, the HRM-PCR method can reduce the running 
cost because PCR primers are the only additional consumable 
required when a new target is discovered. The quality of the 
test result was assured by the combination of the biopsy pro-
cedure itself (containing malignant cells) and the high sensi-
tivity of the method to detect mutations/fusion genes. Thus, 
the total cost for the present analyses was approximately U.S. 
$350 per patient in this study, suggesting that this method 
must be cost-effective. The actual molecular screening cost is 
TABLE 1.  Results of Mutation and Fusion Gene Analyses
Bronchoscopic Samples (n = 48) EBUS-TBNA Samples (n = 86)
Concordant
(Minor Concordant)a
Discrepant
Core/uMS
Concordant
(Minor Concordant)a
Discrepant
Core/uMS
Mutation analysis
EGFR 7 (15%) 1/1 (2/2%) 12 (14%) 0/0 (0/0%)
  L858R 2 0/1 4 0
  E746_A750 del 2 1/0 2 0
  E746_A750 delinsIP 0 0 1 0
  L747_P753 delinsS 1 0 0 0
  L858R+A871G 0 0 1 0
  L858R+c.2361 G>A 2 0 3 0
  L747_P753 delinsS + c.2361 G>A 0 0 1 0
  Silent mutations 5 (10%) 1/2 (2/4%) 14 (16%) 0/0 (0/0%)
   c.2316 C>T 0 0/1 0 0
   c.2361 G>A 5 (1) 1/1 14 0
KRAS 5 (10%) 0/0 (0/0%) 6 (7%) 0/0 (0/0%)
  G12V 1 0 3 (1) 0
  G12C 2 (1) 0 1 0
  G12D 2 (1) 0 1 0
  G13C 0 0 1 0
BRAF 0 (0%) 0/1 (0/2%) 0 (0%) 0/0 (0/0%)
  V600E 0 0/1 0 0
Fusion gene analysis
ALK 1 (2%) 0/0 (0/0%) 4 (5%) 0/0 (0/0%)
  Variant 1 + c.2361 G>A 1 0 1 0
  Variant 2 0 0 1 0
  Variant 3a/b 0 0 1 0
  New variant + c.2361 G>A 0 0 1 0
RET 0 (0%) 0/0 (0/0%) 1 (1%) 0/0 (0/0%)
  CCDC6-RET + c.2361 G>A 0 0 1 0
ROS1 0 (0%) 0/0 (0/0%) 1 (1%) 0/0 (0/0%)
  SCL34A21-ROS1 + c.2361 G>A 0 0 1 0
Wild-type 24 (50%) 0/0 (0/0%) 48 (56%) 0/0 (0/0%)
Total 42 (88%) 2/4 (4/8%) 86 (100%) 0/0 (0/0%)
Concordant: same results were obtained between uMSs and histological samples. Discrepant: mutation was detected only in histological core or uMS.
aMinor concordant: mutations were detected by HRM-PCR analysis, but not identified in sequencing of uMSs.
EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; EGFR, epidermal growth factor receptor; HRM-PCR, high-resolution melting-polymerase chain 
reaction; uMSs, ultra-microsamples.
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listed and compared in Supplementary Table 3 (Supplemental 
Digital Content 1, http://links.lww.com/JTO/A490), and our 
institution absorbed all costs for molecular testing in this study 
because this survey was conducted for research purposes.
In the near future, molecular targeted therapy will become 
the mainstream treatment for anticancer chemotherapy, and 
new agents and corresponding new biomarkers will be found. 
Our screening method is able to accommodate newly discov-
ered biomarkers with only the design of appropriate primer sets 
and may be easy to apply with high sensitivity for known muta-
tions/fusion genes. In addition, using uMS screening methods 
allows for the preservation of small biopsy samples. If needed, 
preserved cores (frozen tissues) or paraffin-fixed cores may be 
used for secondary molecular marker investigations.
There were some limitations to this study. The first 
was the sensitivity of the PCR-based method. Our focus here 
was to show the quality of concordance between biopsy core 
samples and uMSs, and, as emphasized earlier in this article, 
these molecular tests need to be conducted conveniently and 
inexpensively. HRM analysis can achieve these goals by allow-
ing us to perform multiple molecular analyses in one assay. For 
RNA testing, PCR-based methods have been reported to have 
sufficient sensitivity,17 whereas for DNA testing, previously 
reported methods (e.g., peptide nucleic acid–locked nucleic 
acid PCR-clamp methods,18 Scorpion amplification refractory 
mutation system methods,19 etc.) showed higher sensitivity, 
allowing detection of mutations with 1% of the tumor amount; 
HRM analysis requires greater than 5% of the tumor amount 
to achieve sufficient molecular analysis.20 For the verifica-
tion of molecular analysis, we also surveyed the tumor ratio 
of core samples and uMSs in 20 randomly selected samples 
in our series, which could be evaluated both pathologically 
and cytologically. All these core samples and uMSs showed 
greater than 5% tumor content. Furthermore, we also analyzed 
EGFR mutations by the PCR-clamp method for verification 
in 15 cases, and the results were completely concordant with 
the results of HRM analysis. Therefore, we propose that this 
study limitation is acceptable, and we now need to explore 
FIGURE 3.  DNA and cDNA analyses for EGFR, KRAS, and BRAF mutation and ALK, RET, and ROS1 fusion genes. HRM analysis 
and direct sequencing of EGFR-, KRAS-, and BRAF-positive samples are shown (A–C). The blue baseline shows the HRM curve of 
the wild-type sample, and the red curves show the existence of each mutation (A: EGFR exon21, L858R; B: KRAS exon12, G12D; 
C: BRAF V600E) by HRM analysis. Loci were identified by direct sequencing by using the PCR products from HRM analysis. HRM 
analysis and direct sequencing of EML4-ALK–, CCDC6-RET– and SCL34A2-ROS1–positive samples are shown (D–F). D, HRM 
curves for EML4-ALK variant 1 (uMS) and variant 2 (histological core and uMS) and the results of direct sequencing. Each vari-
ant showed a different curve. E, HRM curve and sequencing for CCDC6-RET fusion gene–positive samples. F, HRM curve for the 
TPM3-ROS1 fusion sequence (artificial sequence for the positive control) and HRM curve for the detected SCL34A2-ROS1 fusion 
gene. The sequence of the SCL34A2-ROS1 fusion gene was identified. EGFR, epidermal growth factor receptor; ALK, anaplastic 
lymphoma kinase; ROS1, receptor tyrosine kinase; uMS, ultra-microsample; HRM, high-resolution melting; PCR, polymerase 
chain reaction; KRAS, K-rat sarcoma; BRAF, B-rapidly accelerated fibrosarcoma.
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the respective high-sensitivity methods for each genetic disor-
der to improve sensitivity. Further investigations are required 
to compare the sensitivity between mass samples and biopsy 
samples.
The second limitation of this study was the heteroge-
neity of the tumors. Bronchoscopic or EBUS-TBNA samples 
represented only partial sections and may not have been rep-
resentative of the whole tumor in heterogeneous lung cancer. 
This issue is common in the analysis of microsamples and is 
difficult to overcome because this problem arises from the 
nature of the tumor itself. Metastatic lesions sometimes show 
different genetic profiles from the primary resected tumor,21 
so this limitation may not even be overcome by using large 
operational specimens. Repeated biopsy of the same target 
lesion is one way to reduce this limitation, and from this point 
of view, analysis by uMS may lessen this limitation by rep-
resenting accumulated malignant cells from multiple biopsy 
procedures.
The third limitation was that a single gene-analysis 
modality was applied for all uMSs. Especially for fusion 
gene detection, we have previously reported that multimodal 
analyses are desirable.9 This screening method using uMSs 
was specialized for molecular analysis, and, because only one 
third of uMSs showed malignant cells, pathological evaluation 
was limited by using uMS. For multimodal analysis, histologi-
cal cores can be used for fluorescent in situ hybridization or 
immunohistochemistry if needed and may allow for improved 
sensitivity by additional molecular surveys.
In conclusion, appropriately prepared uMSs, in addition to 
histological core samples, are useful for multiple molecular pro-
filing with respect to accuracy, cost, and convenience in NSCLC.
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TABLE 2.  Differences between Core Samples and uMSs
Pathological evaluation uMS
Malignant cell (+) Malignant cell (−)
Histologic core
  Malignant cell (+) 89 cases 45 cases
  Malignant cell (−) 0 0
Molecular test uMS
Mutation/fusion  
detected
Wild-type
Histologic core
Mutation detected 64 + 4a tests 2 tests
Wild-type 4 tests 1400 tests
Molecular analysis required 11 tests for every 134 samples, with 1474 tests in total. 
Mutation/fusion gene detection was based on HRM-PCR analysis. Test concordance rate 
was 99.4% (1465 of 1474) in the genetic analyses.
aMutations were detected by HRM-PCR analysis, but not identified in sequencing 
of uMSs.
HRM-PCR, high-resolution melting-polymerase chain reaction; uMSs, ultra-
microsamples.
